Boxer Capital Management
San Diego, CAfiles as Boxer Capital Management, LLC
$1.3bn in 63 US stocks at the end of 30 June 2026. The top 10 are 65.1% of the money. It changed about 21.7% of the portfolio this quarter.
Value
$1.3bn
Stocks
63
Top 10 share
65.1%
Turnover
21.7%
What changed this quarter
New
Bought for the first time this quarter.
- Q32 BioQTTB3.0% of the fund
- Spyre TherapeuticsSYRE0.7% of the fund
- Relay TherapeuticsRLAY0.6% of the fund
- Kazia TherapeuticsKZIA0.6% of the fund
- Shattuck LabsSTTK0.5% of the fund
- Forte Biosciences0.4% of the fund
- Odyssey TherapeuticsODTX0.4% of the fund
- ImmaticsIMTX0.4% of the fund
- Faeth TherapeuticsFTH0.3% of the fund
- Neumora TherapeuticsNMRA0.3% of the fund
- MapLight TherapeuticsMPLT0.2% of the fund
- Edesa BiotechEDSA0.1% of the fund
Added
Bought more of a stock they already held.
- Abivax SAABVX6.1% of the fund+203%
- uniQureQURE5.2% of the fund+127%
- Kodiak SciencesKOD4.3% of the fund+9%
- Kymera TherapeuticsKYMR3.7% of the fund+30%
- Definium TherapeuticsDFTX3.5% of the fund+67%
- Replimune GroupREPL3.3% of the fund+239%
- CelcuityCELC3.3% of the fund+85%
- Capricor TherapeuticsCAPR2.5% of the fund+136%
- PrecigenPGEN2.2% of the fund+47%
- Corcept TherapeuticsCORT2.2% of the fund+34%
- SurrozenSRZN2.0% of the fund+44%
- Ocular TherapeutixOCUL1.0% of the fund+271%
- Opus GeneticsIRD0.9% of the fund+25%
- Avalo TherapeuticsAVTX0.5% of the fund+25%
- Helus PharmaHELP0.4% of the fund+23%
- Oric PharmaceuticalsORIC0.3% of the fund+98%
- Inovio PharmaceuticalsINO0.2% of the fund+20%
Cut
Sold some of their stake.
- Allogene TherapeuticsALLO0.2% of the fund-45%
Sold out
Sold their entire stake.
- Terns Pharmaceuticals-100%
- Soleno Therapeutics-100%
- Kalvista Pharmaceuticals-100%
Holdings
- Abivax SAABVX
- Share
- 6.1%
- Value
- $81m
- Shares
- 605,000
+203%
- Apogee TherapeuticsAPGE
- Share
- 0.7%
- Value
- $9m
- Shares
- 70,000
Held
- Kazia TherapeuticsKZIA
- Share
- 0.6%
- Value
- $8m
- Shares
- 560,000
New
- Forte Biosciences
- Share
- 0.4%
- Value
- $6m
- Shares
- 274,500
New
- Helus PharmaHELP
- Share
- 0.4%
- Value
- $5m
- Shares
- 790,000
+23%
- Odyssey TherapeuticsODTX
- Share
- 0.4%
- Value
- $5m
- Shares
- 275,000
New
- Structure TherapeuticsGPCR
- Share
- 0.3%
- Value
- $4m
- Shares
- 75,000
Held
- Surrozen
- Share
- <0.1%
- Value
- $1,067
- Shares
- 66,666
Held
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| Tango TherapeuticsTNGX | 25.6% | $340m | 10,876,219 | Held |
| Revolution MedicinesRVMD | 7.1% | $94m | 500,000 | Held |
| Abivax SAABVX | 6.1% | $81m | 605,000 | +203% |
| uniQureQURE | 5.2% | $69m | 1,503,300 | +127% |
| Kodiak SciencesKOD | 4.3% | $58m | 1,477,600 | +9% |
| Kymera TherapeuticsKYMR | 3.7% | $49m | 429,100 | +30% |
| Definium TherapeuticsDFTX | 3.5% | $47m | 998,500 | +67% |
| Replimune GroupREPL | 3.3% | $44m | 3,983,000 | +239% |
| CelcuityCELC | 3.3% | $44m | 416,530 | +85% |
| Q32 BioQTTB | 3.0% | $40m | 3,149,310 | New |
| Capricor TherapeuticsCAPR | 2.5% | $34m | 1,395,156 | +136% |
| PrecigenPGEN | 2.2% | $29m | 5,150,000 | +47% |
| Corcept TherapeuticsCORT | 2.2% | $29m | 335,500 | +34% |
| SurrozenSRZN | 2.0% | $27m | 1,105,683 | +44% |
| Protagonist TherapeuticsPTGX | 1.6% | $21m | 170,000 | Held |
| Vir BiotechnologyVIR | 1.4% | $19m | 1,866,000 | Held |
| VaxcytePCVX | 1.4% | $19m | 325,000 | Held |
| UroGen PharmaURGN | 1.4% | $18m | 500,000 | Held |
| Corvus PharmaceuticalsCRVS | 1.2% | $16m | 1,100,000 | Held |
| PTC TherapeuticsPTCT | 1.2% | $16m | 200,000 | Held |
| Praxis Precision MedicinesPRAX | 1.2% | $16m | 46,457 | Held |
| Amylyx PharmaceuticalsAMLX | 1.1% | $14m | 800,000 | Held |
| Ocular TherapeutixOCUL | 1.0% | $13m | 1,300,000 | +271% |
| Opus GeneticsIRD | 0.9% | $12m | 2,815,000 | +25% |
| Palisade BIOPALI | 0.8% | $10m | 4,799,875 | Held |
| Apogee TherapeuticsAPGE | 0.7% | $9m | 70,000 | Held |
| Spyre TherapeuticsSYRE | 0.7% | $9m | 100,000 | New |
| Cogent BiosciencesCOGT | 0.7% | $9m | 225,000 | Held |
| CytokineticsCYTK | 0.6% | $9m | 100,000 | Held |
| Relay TherapeuticsRLAY | 0.6% | $8m | 450,000 | New |
| Crescent BiopharmaCBIO | 0.6% | $8m | 453,686 | Held |
| Contineum TherapeuticsCTNM | 0.6% | $8m | 494,000 | Held |
| Kazia TherapeuticsKZIA | 0.6% | $8m | 560,000 | New |
| Shattuck LabsSTTK | 0.5% | $7m | 1,000,000 | New |
| Avalo TherapeuticsAVTX | 0.5% | $7m | 375,000 | +25% |
| Forte Biosciences | 0.4% | $6m | 274,500 | New |
| Relmada TherapeuticsRLMD | 0.4% | $6m | 842,106 | Held |
| MoonLake ImmunotherapeuticsMLTX | 0.4% | $5m | 275,000 | Held |
| Zura BioZURA | 0.4% | $5m | 900,000 | Held |
| Helus PharmaHELP | 0.4% | $5m | 790,000 | +23% |
| Odyssey TherapeuticsODTX | 0.4% | $5m | 275,000 | New |
| ImmaticsIMTX | 0.4% | $5m | 475,000 | New |
| Faeth TherapeuticsFTH | 0.3% | $5m | 180,505 | New |
| Structure TherapeuticsGPCR | 0.3% | $4m | 75,000 | Held |
| Oric PharmaceuticalsORIC | 0.3% | $4m | 350,000 | +98% |
| AN2 TherapeuticsANTX | 0.3% | $4m | 749,035 | Held |
| Neumora TherapeuticsNMRA | 0.3% | $3m | 2,000,000 | New |
| Inovio PharmaceuticalsINO | 0.2% | $3m | 2,844,994 | +20% |
| Allogene TherapeuticsALLO | 0.2% | $3m | 1,500,000 | -45% |
| Solid BiosciencesSLDB | 0.2% | $3m | 300,000 | Held |
| Karyopharm TherapeuticsKPTI | 0.2% | $3m | 302,536 | Held |
| CleneCLNN | 0.2% | $3m | 477,515 | Held |
| Sarepta TherapeuticsSRPT | 0.2% | $3m | 150,000 | Held |
| MapLight TherapeuticsMPLT | 0.2% | $3m | 75,000 | New |
| Nurix TherapeuticsNRIX | 0.2% | $2m | 100,000 | Held |
| LB PharmaceuticalsLBRX | 0.2% | $2m | 70,000 | Held |
| Edesa BiotechEDSA | 0.1% | $2m | 205,000 | New |
| InvivydIVVD | <0.1% | $1m | 1,500,000 | Held |
| Upstream BioUPB | <0.1% | $1m | 150,000 | Held |
| Milestone PharmaceuticalsMIST | <0.1% | $893,332 | 666,666 | Held |
| PepGenPEPG | <0.1% | $491,206 | 272,892 | Held |
| RegenxbioRGNX | <0.1% | $179,700 | 15,000 | Held |
| Surrozen | <0.1% | $1,067 | 66,666 | Held |
Over time and by industry
Value over time
Jun '25
Dec '25
Jun '26
Value is up 568.4% since 30 June 2025.
Where the money is
Health care92.6%
Other7.4%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.